home / stock / xphyf / xphyf news


XPHYF News and Press, XPhyto Therapeutics Corp From 06/17/21

Stock Information

Company Name: XPhyto Therapeutics Corp
Stock Symbol: XPHYF
Market: OTC

Menu

XPHYF XPHYF Quote XPHYF Short XPHYF News XPHYF Articles XPHYF Message Board
Get XPHYF Alerts

News, Short Squeeze, Breakout and More Instantly...

XPHYF - InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp.

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of an exclusive The Bell2Bell P...

XPHYF - 420 with CNW - Congressional Bill Could Enable Researchers to Study Cannabis from Dispensaries

Earlier this week, a congressional committee revealed its plans to vote on a legislation that will enable scientists to study cannabis products from state-legal dispensaries. The 1,200-page legislation , which has been advanced to the House Transportation and Infrastructure Committee, wil...

XPHYF - Study Finds Coronavirus Pandemic Significantly Impacted Adolescents' Mental Health

A study carried out by a group of social and behavioral researchers from North America and Iceland has discovered that the coronavirus has had a harmful effect on adolescent mental health , particularly in girls. This study is the first to look into and record the gender and age-specific ch...

XPHYF - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Commences Sale of Rapid COVID-19 RT-PCR Test Kits in Germany Amid Potential Surge in Demand

XPhyto’s distribution, storage, and logistics partner, Max Pharma GmbH, began the sale and delivery of its rapid test kits (Covid-ID Labs) in Germany on May 25 Max Pharma will sell Covid-ID Labs at volume-dependent pricing comparable to other COVID-19 PCR test products on the mar...

XPHYF - XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment oppor...

XPHYF - Study Finds Americans Are Receptive to Psychedelic Treatments

The coronavirus pandemic has not only affected the economies of different countries as well as industries around the world, but it has also affected the mental and emotional health of millions of individuals globally. Field Trip Health , one of the biggest providers of psychedelic therapi...

XPHYF - InvestorNewsBreaks - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update on Timely Progression of Psychedelic Medicine Program

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that its GMP mescaline synthesis program is on schedule with the completion of initial production batches. According to the update, the industrial-scale manufacture of pharmaceutical-grade psychedelic compounds, incl...

XPHYF - 420 with CNW - Study Finds That CBD May Improve Overall Wellness

A few months ago, results of a preliminary study on the effect of CBD on the liver were released by Validcare . The company then released a separate report on the use of CBD among Americans, which was carried out in collaboration with Cannabis Business Experts (“CBE”), a mar...

XPHYF - XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies

Research and development lab set up, preliminary mescaline synthesis complete Modified synthesis process developed, mescaline batches manufactured Development of analytical methods and validation, GMP standard operating procedures and manufacturing scale-up underway VANCOUVER...

XPHYF - XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Beginning 2021 Strong with New Drugs and Life Sciences Advancements

Promising results have been recorded in the first pilot study of a Rotigotine skin patch for Parkinson’s patients Wholly owned subsidiary Vektor is reaching a major milestone in the development of Rotigotine with the potential for a pivotal human trial The company is planning t...

Previous 10 Next 10